The EWS-FLI1 transcription factor is consistently expressed in 85% of Ewing tumors (EFT). In heterologous cells, EWS-FLI1 induces p53-dependent cell cycle arrest or apoptosis. It has been speculated that the p53 tumor suppressor pathway may be generally compromised in EFT despite only rare p53 mutations. In order to test for functional integrity of this pathway, we have investigated a series of EFT cell lines that differ from each other with respect to their endogenous p53 and INK4A gene status for their response to ectopic p53 expression and to stimulation of endogenous p53 activity by X-ray treatment. Significant interindividual and intratumoral variations in the apoptotic propensity of EFT cell lines to transient expression of ectopic p53 were observed, which was independent of the level of p53 expression. In cell lines with a low apoptotic incidence, apoptosis was delayed and the surviving fraction showed a prolonged growth arrest. Complete resistance to p53-induced apoptosis in two cell lines established from the same patient was associated with a high BCL2/BAX ratio and low levels of APAF1. Sensitivity to X-rays showed a trend towards a higher apoptotic rate in wild-type (wt) p53 expressing than in p53 mutant cells. However, one wt p53-expressing EFT cell line was completely refractory to irradiation-stimulated cell death despite high apoptotic responsiveness to ectopic p53. No difference in Ser15 phosphorylation and the transcriptional activation of p53 targets was observed in wt p53 EFT cell lines irrespective of the induction of cell death or growth arrest. All together, our results demonstrate that despite significant variability in the outcome, cell death or cell cycle arrest, the p53 downstream pathway and the DNA damage signaling pathway are functionally intact in EFT.
Introduction
Ewing's sarcoma family tumors (EFT) are a group of aggressive pediatric small-round-cell tumors characterized by an EWS gene rearrangement with a member of the ets transcription factor gene family . Since EWS-ets gene rearrangements are associated with at least 95% of EFT, they are considered to be causative for the disease. Comparison between the genomic breakpoints and the structure of the fusion mRNA of the most frequent EWS-ets fusion in EFT, EWS-FLI1, revealed selective pressure for maintenance of a correct reading frame (Zucman et al., 1993; Zucman-Rossi et al., 1998) . Antisense DNA studies confirmed that continuous EWS-FLI1 expression is required for EFT cell proliferation in vitro and tumorigenicity in vivo (Ouchida et al., 1995; Kovar et al., 1996; Tanaka et al., 1997; Toretsky et al., 1997) . In contrast, ectopic expression of EWS-FLI1 in heterologous cellular systems results in cell cycle arrest or cell death, which was recently demonstrated to be accompanied by and dependent on the transcriptional induction of p53 and its downstream genes (Deneen and Denny, 2001; Lessnick et al., 2002) .
The p53 protein is a sensor of multiple forms of genotoxic, oncogenic and nongenotoxic stress. It suppresses growth and controls survival of stressed cells, and as such, is the focal point of selection pressures in tissues exposed to carcinogens or to oncogenic changes (for a recent review see Guimaraes and Hainaut, 2002) . P53 function is compromised in the majority of human malignancies by mutation of the p53 gene (Hainaut et al., 1998) or by altered expression of gene products that impact on the stability and activity of the p53 protein or of other components of the pathway (i.e. p14 ARF , HDM2, adenovirus E6 protein) (Haupt et al., 1997; Kubbutat et al., 1997; Stott et al., 1998; Zhang et al., 1998; Thomas et al., 1999) . Regulation of p53 occurs primarily on the post-translational level. Different types of cellular stress induce different but overlapping patterns of protein modifications that lead to stabilization of p53 and activation of its transcriptional activity. Induction of p53 by oncogenes frequently involves the alternative INK4A gene product p14 ARF . In contrast, ectopic expression of the EWS-FLI1 oncogene in hTERT immortalized human fibroblasts was demonstrated to induce p53 on the transcriptional level (Lessnick et al., 2002) . Since EWS-FLI1 toxicity can be attenuated in p53-or INK4A-deficient mouse embryo fibroblasts (Deneen and Denny, 2001) , it has been speculated that the p53 checkpoint pathway is generally impaired in EFT. However, p53 mutations and HDM2 amplification rarely occur in primary EFT (Kovar et al., 1993b; Hamelin et al., 1994; Ladanyi et al., 1995) and INK4A gene loss is observed in only 20-30% of cases (Kovar et al., 1997; Wei et al., 2000) . The proposed presence of adenoviral gene products that may disrupt the p53 pathway in EFT (Sanchez-Prieto et al., 1999) could not be confirmed (Kovar et al., 2000a) . Thus, the basis for tolerance of EFT cells to EWS-FLI1 expression remains elusive.
Although usually responding very well to initial chemo-and radiation therapy, about one-third of EFT patients with localized disease and the majority of patients with metastases at diagnosis relapse and eventually die from the disease, suggesting the existence of treatment-resistant tumor cell subclones escaping DNA-damaging therapy. Although relatively rare, p53 mutation and INK4A deletion have been demonstrated to characterize a subset of patients with a particularly bad prognosis Wei et al., 2000) . Since, in EFT, tumor cells carrying these types of genetic alterations can be preferentially expanded in vitro leading to a greatly increased incidence of p53 mutations and INK4A gene loss in EFT cell lines (Kovar et al., 1993a (Kovar et al., , 1997 , it is possible that cell lines may be representative of a treatment-resistant cell population in the primary tumors involving alterations in DNA checkpoint control. However, the functionality of the p53 pathway in EFT cell lines, in particular those that retain wild-type (wt) p53 status, has not been addressed yet.
In order to test for the functional integrity of the DNA-damage response and of the pathway downstream of p53 activation, we sought to evaluate the apoptotic propensity of EFT cell lines with different endogenous p53 and INK4A gene status upon genotoxic treatment and in response to isolated ectopic p53 overexpression.
Results

Response of EFT cell lines with different endogenous p53 gene status to X-rays
The status of p53, INK4A and MDM2 genes of EFT cell lines used in this study are summarized in Table 1 . We first investigated the expression of p53 target genes WAF1, HDM2, BAX, PIG3 and DR5 upon X-irradiation (6 Gy) on Northern blots as a surrogate marker for intact DNA-damage signaling to p53. Figure 1a demonstrates the results for three wt p53 EFT cell lines (TC252, VH64 and STA-ET-1) and for SK-N-MC, as an example of a p53 mutant cell line for comparison. All five genes tested were significantly induced in the three wt p53-expressing cell lines although some variability in Figure 1 (a) Inducibility of p53 target genes in EFT cell lines by X-rays. Northern blot of total RNA extracted from three wt p53-expressing and one p53-mutant EFT cell lines at 0, 2, 4, 7, 10 and 24 h postirradiation with 6 Gy. (b) Western blot of proteins extracted from wt p53-expressing EFT cell lines 0, 8, and 24 h after irradiation with 6 Gy. The double band observed for p53 in cell lines VH64 and STA-ET-1 results from the presence of a heterozygous R72P polymorphism. A Ponceau S stain of the filter is shown for loading control the strength and duration of the transcriptional response was noted. WAF1, HDM2 and DR5 expression peaked at 4 h, while BAX reached maximum expression at 7 h postirradiation. PIG3 was variably and only slightly induced with maximum levels at 7 h. Stimulation of WAF1 and DR5 expression was highest and sustained in VH64 and STA-ET-1 cells, while in TC252 cells induction of these two genes was moderate and transient. The highest increase in HDM2 expression was noted in VH64 cells. BAX induction was comparable in all three cell lines and PIG3 expression was generally low. In contrast, as expected, none of these genes was found to be induced in the p53-null cell line SK-N-MC.
On the protein level (Figure 1b) , p53 was similarly increased in all three wt p53 EFT cell lines in response to X-irradiation. Despite induction on the RNA level, no increase in BAX protein was noted. BCL2, known to be suppressed by p53 in some cellular systems, was decreased only in STA-ET-1 cells at 24 h postirradiation.
Since the conversion of poly (ADP-ribose) polymerase (PARP) species p113 to p89 in TC252 and STA-ET-1 cells indicated caspase activation (Figure 1b) , we next tested for radiation-induced apoptosis. Four and three EFT cell lines with wt and mutant p53 status, respectively, were X-irradiated with doses between 0 and 12 Gy, and cell death was assessed by trypan blue staining 23, 33, and 43 h post-treatment (Figure 2a ). All cell lines except one (VH64) showed a dose-and timedependent increase in cell death. Dead cells were predominantly found in the supernatant, suggesting detachment of irreversibly damaged cells from the fibronectin-coated plastic as a consequence of apoptosis. DAPI staining of adherent and detached cells confirmed almost exclusive confinement of nuclear fragmentation and the presence of apoptotic bodies to floating cells. The size of the apoptotic fraction was generally higher in wt p53 than in p53 mutant cell lines with the exception of VH64 cells only. These results indicate a supportive role of p53 in radiation-induced cell death of EFT cells. In VH64 cells, X-irradiation did not elicit an apoptotic response, compatible with the complete lack of PARP cleavage, but rather resulted in a transient G2 and a stable G1 arrest (Figure 2b) .
Ionizing radiation-induced DNA-damage signaling to p53 involves protein kinases ATM, ATR and DNA-PK, which phosphorylate p53 at Ser15 (Durocher and Jackson, 2001) . Recently, DNA-PK activity has been reported to be essential for p53-induced apoptosis in response to X-rays (Woo et al., 2002) . We, therefore, tested for Ser15 phosphorylation in two wt p53-expressing EFT cell lines that differ in the type of response to ionizing irradiation, cell death (STA-ET-1) or cell cycle arrest (VH64) (Figure 3a ). No differences in the extent of Ser15 modification upon X-ray treatment were observed, confirming intact DNA-damage signaling in EFT cells independent of the functional outcome.
Apoptotic responsiveness of EFT cell lines to transiently transfected p53
DNA-damage-induced accumulation of p53 results from increased protein stability as a consequence of post-translational modification. In contrast, EWS-FLI1 has been demonstrated to induce p53 on the RNA level (Lessnick et al., 2002) . In order to mimic p53 accumulation because of increased gene expression, we investigated the apoptotic response to ectopic CMV promoter-driven p53 expression in wt and mutant p53 EFT cells. In contrast to the irradiation experiments, this approach resulted in only very weak Ser15 phosphorylation of ectopically overexpressed p53 ( Figure 3b) .
A flow cytometric assay, similar to an established protocol (Yonish-Rouach et al., 1994; Friedlander et al., 1996) was used to analyse the DNA content of EFT cells transiently expressing ectopic p53. Briefly, 44 h posttransfection with different p53 or control expression constructs, cells were collected from the supernatant and combined with cells detached from the plastics by trypsinization. Transgene expressing EFT cells were identified using a p53 specific antibody or, in pCMV-SVNL control transfections, using a b-galactosidase specific antibody, and DNA content was assessed by staining with propidium iodide (PI) (for flow cytometry) or DAPI (for microscopic evaluation). This procedure allowed us to evaluate the cell cycle distribution of identically treated cells in a culture in the absence of selective pressure, distinguishing between successfully transfected and untransfected cells. This distinction is based upon the increase in fluorescence intensity of cells expressing ectopic on top of endogenous p53, even if the latter is in a mutant conformation. Note that this approach is completely independent from the transfection efficiency and thus allows for the comparison of different cell lines. We extensively studied the apoptosisinducing potential of wt p53 and, for control, mutant (R273 H) p53. Figure 4a presents the size of the p53-or control transgene-expressing fraction with a sub-G1 DNA content. At 44 h post-transfection, most cell lines showed between 50% (STA-ET-1, IARC-EW2) and 70% (TC252, SK-N-MC, VH64) cell death. In contrast, only about 25% and less than 10% of SAL2, and STA-ET-2.1 and STA-ET2.2 cells had died, respectively. These differences were found to be statistically significant by means of the exact Wilcoxon two-sample test. Note that STA-ET-1 and SAL2 cell lines and STA-ET-2.1 and STA-ET-2.2 cell lines were independently obtained from the same tumor sample, respectively, from the same patient. While the latter pair of cell lines behaved similarly resistant towards wt p53-induced cell death, the former pair displayed heterogeneity in apoptotic cell death despite being similarly sensitive to X-rays ( Figure 2a ). Figure 4b presents the dot blots for TC252, SAL2 and STA-ET-2.2 representative for the three different types of outcome observed. In TC252 cells, wt p53 overexpression resulted predominantly in cell death, as evident from the accumulation of p53 (Figure 4c) . In contrast for cell lines SAL2 and STA-ET-2.2, cells expressing ectopic p53 were primarily (SAL2) or almost exclusively (STA-ET-2.2) confined to the G1-phase fraction.
In the cell lines IARC-EW2 and SK-N-MC, which are mutant for and lacking endogenous p53, but sensitive to ectopically expressed wt p53, weak residual apoptotic activity above control levels (obtained by pCMV-SVNL transfection) was observed with the DNA binding mutant p53-273 H. This effect was masked in EFT cells carrying a wt p53 gene owing to apoptosis elicited by mere DNA delivery as indicated by the apoptotic response to a control nuclear-LacZ expression plasmid (pCMV-SVNL). This result may confirm earlier observations that transfected DNA imparts a DNA damage signal because of the presence of strand breaks which will elicit a p53 response in wt cells (Renzing and Lane, 1995) . The only exception was SAL2, which generally displayed reduced sensitivity to wt p53-mediated apoptosis. Surprisingly, the cell line VH64, which was found to be completely resistant to irradiation-induced cell death, was found to be highly sensitive to ectopically expressed p53. Similar to all other wt p53-expressing cell lines sensitive to ectopic p53 expression, DNA transfection per se also induced a strong apoptotic response. As can be seen in Figure 3b , transfection of a control plasmid (GFP) into VH64 cells led to an increase in endogenous p53 levels without causing Ser15 phosphorylation, compatible with a different mechanism of endogenous p53 activation.
In summary, the transient transfection assays indicated variability in the apoptotic responsiveness of EFT cell lines to forced p53 expression independent from the endogenous p53 gene status.
It has been suggested previously that the level of induced p53 expression would determine the fate of a cell, either to enter into cell cycle arrest or to apoptose (Chen et al., 1996) . In order to identify a possible relation between the level of ectopic p53 and the extent of apoptosis in EFT cells, the proportion of cells with a sub-G1 DNA content was flow-cytometrically evaluated in three windows of increasing p53 immunoreactivity. Figure 5 clearly demonstrates that the proportion of sub-G1 cells was similarly low in SAL2 (Figure 5b, d ) and similarly high in TC252 cells (Figure 5a, d ) in all the three windows analysed. While the amount of p53 in windows 2 and 3 may be unphysiologically high, cells within window 1 contain p53 at a level similar to cells treated with DNA-damaging agents, as demonstrated for actinomycin D in Figure 5c . These data suggest the absence of any correlation between the number of apoptotic cells and their p53 content above the background.
The differences in the size of the apoptotic fraction of wt p53-transfected cells may result from different kinetics of apoptosis in the various cell lines. Cells that enter into apoptosis early may have already lost p53 immunoreactivity or may even have disintegrated at 44 h and therefore escape detection in our assay. We have previously demonstrated that mitochondrial breakdown and nuclear DNA fragmentation in EFT cells expressing temperature-sensitive p53 are first detectable around 18 h after induction of the wt conformation (Kovar et al., 2000b) . We therefore studied the three EFT cell lines TC252, SAL2 and STA-ET-2.2, which, at 44 hours, had displayed the most striking differences in p53-induced apoptosis, in a time course experiment between 24 and (Figure 6a ). After that time, the apoptotic fraction increased in size with different slopes, reaching maximum levels at 36 h (about 80%) for TC252 cells and at 48 h (about 35%) for SAL2 cells. Little to no change was observed for STA-ET-2.2 cells. The remaining p53-positive fraction (20% of TC252, 75% of SAL2, almost all STA-ET-2.2 cells) appeared to be resistant to the p53-induced apoptosis since no further increase in the apoptotic fraction was observed at later times. Thus, the difference in the apoptotic propensity of different EFT cell lines in response to wt p53 results from both different kinetics and different maximum levels of cell death. In the same time course experiment, cell cycle changes in the surviving fraction were followed by flow cytometry. During the first 24 h after transfection, the proportion of S-phase cells dropped significantly in SAL2 and TC252 cells. Whether this effect was solely caused by early ectopic wt p53 expression or also by transfection-stimulated induction of endogenous wt p53 could not be distinguished, since a similar effect was seen early after pCMV-SVNL transfection in some, but not all EFT cell lines (data not shown). Thereafter, the surviving fraction of TC252 rapidly recovered, while SAL2 showed a pronounced and much more persistent decrease in the number of S-phase cells never approaching control levels again. In contrast, STA-ET-2.2 cells displayed a small but sustained growth reduction of about 20% (Figure 6b ). These results suggest that in response to forced wt p53 expression, the majority of EFT cells lose viability because of either cell death or cell cycle arrest. However, a small but a variable fraction of cells escape inactivation by overexpressed p53.
Expression of apoptosis-related genes in EFT cell lines
Since EFT cell lines had shown variable apoptotic responsiveness to forced p53 expression, basal levels of proteins known to play a role in p53-induced apoptosis of EFT cells (Kovar et al., 2000b) were assessed on the Western blot. Figure 7 demonstrates that only the pair of cell lines found to be resistant to p53-induced cell death (STA-ET-2.1 and STA-ET-2.2) showed a high BCL2/BAX ratio and reduced expression of APAF1. In contrast, despite a lower apoptotic propensity, SAL2 showed lower BCL2 expression levels than its sister cell line STA-ET-1. All other EFT cell lines, including radiation-resistant VH64, displayed similar BCL2 expression levels. These data indicate that BCL2 is not generally responsible for differences in the apoptotic behaviour of EFT cell lines. Some variability in basal expression levels was observed for BCL-X 1 and caspase 8, but not for caspase 9. However, no correlation to different apoptotic sensitivity of EFT cell lines could be drawn. Previously, using embryonic fibroblasts from p53-deficient mice, a modulatory role of p53-dependent apoptosis on the cytotoxicity of anticancer agents was established (Lowe et al., 1993) . Since the NCI drug screen did not contain cell lines from typical pediatric malignancies, which carry p53 mutations in the primary tumors at a much lower frequency than tumors in adults, this study was conducted to evaluate the response of cancer cell lines derived from one tightly defined childhood tumor entity to forced p53 expression, and its possible contribution to therapy resistance of the disease. We chose EFT, since experimental data suggested a deficiency in the p53 pathway of cells tolerating expression of the EFT-specific EWS-FLI1 fusion gene despite rare mutation of the p53 gene itself (Deneen and Denny, 2001; Lessnick et al., 2002) . There is ample evidence from various human malignancies that cancer-derived mutations in the p53 gene or other genes of the pathway, which may result from a selective pressure to escape oncogenic stress, generally affect genome surveillance, cell cycle control and cell death. However, our results indicate that the p53 downstream pathway is not generally impaired in EFT cells. The results obtained in the irradiation experiments essentially confirm the conclusions drawn from the analysis of the NCI Anticancer Drug Screen cell line panel in that the presence of wt p53 correlated with a higher sensitivity to DNA-damage-induced cell death. Ser15 phosphorylation, stabilization of p53 and the activation of p53 target genes upon X-irradiation indicated correct signaling of DNA damage to wt p53. Also, forced p53 expression in EFT cells was found to result in the known downstream functional consequences, cell death and cell cycle arrest. Thus, it appears that tolerance of EFT to EWS-FLI1 expression is mediated by mechanisms affecting signaling of oncogenic stress upstream of p53 in most cases.
Previous in vivo studies (Midgley et al., 1995) as well as investigations on a variety of cell lines suggested that the type of response of a cell line to forced p53 expression is cell-type specific. EFT presumably origi- nate from a tightly defined immature cell type of neuroectodermal histogenesis (for a review see Kovar, 1998) . Our results reveal that for EFT, cell death or growth arrest are not mutually exclusive tumor-specific responses to p53. Rather, we observed variability in the extent of the apoptotic response to transient high-level p53 expression of individual EFT cell lines that was independent of the endogenous p53 and INK4A gene status. When analysing pairs of cell lines derived from the same tumor or from independent tumor samples of the same patient, both intratumoral as well as interindividual variations in apoptotic propensity were observed. Using an assay that allows to compare transfected to untransfected cells within the same culture vessel and to correlate p53 expression to apoptosis on a single cell level, we were able to demonstrate that a variable and cell-line-specific number of EFT cells escape cell death upon transiently increased p53 expression. This situation is reminiscent of the transient induction of endogenous p53 upon cyclic administration of anticancer agents during therapy. No correlation between the level of p53 protein and the extent of cell death was observed, suggesting that the hypothesis that p53 levels may determine the fate of the cell to die or to enter into growth-arrest is not applicable to EFT cell lines (Chen et al., 1996) . Our data show that in apoptosis-proficient cells, p53-induced cell death is a rapid process independent from the level of p53 overexpression. In the cell line SAL2, we observed a low incidence of apoptosis in response to p53, which was delayed by 12-24 h when compared to apoptosisproficient TC252 cells despite similar growth rates of the cell lines. The delay and low extent of apoptosis in SAL2 was paralleled by a pronounced cell cycle arrest of p53 overexpressing survivors. Thus, the low apoptotic sensitivity of the SAL2 cell line may reflect a genuine apoptotic disability supporting the growth arresting activity of p53. Cytogenetically, although derived from the same tumor, STA-ET-1 and SAL2 cell lines differ from each other by a single aberration: In contrast to apoptosis-proficient STA-ET-1 cells, SAL2 cells harbor a 1p36 allelic deletion (Hattinger et al., 1999) . This aberration is frequently encountered in neuroectodermal tumors including neuroblastoma and melanoma. Recently, chromosomal imbalances of this region have been discussed as associated with poor prognosis in a subset of EFT patients (Hattinger et al., 1999) . This region is extraordinarily rich in putative apoptotic genes, including the genes for p34 cdc2 -related PITSELRE kinases (Lahti et al., 1995) , TNF receptor 2 and the TNF-related receptor DR3 (Beltinger et al., 1996; Grenet et al., 1998) , caspase 9 (Hadano et al., 1999) and the caspase-activated DNase CAD (Mukae et al., 1998) , the transcription factor RUNX3 involved in TGFb apoptotic signaling (Li et al., 2002) as well as the p53 related p73 (Ichimiya et al., 1999) . It remains to be established if any of these genes are differentially expressed between SAL2 and STA-ET-1 cells, possibly explaining the observed differences of these cell lines in the extent of p53-induced cell death. It is tempting to speculate, however, that 1p36 deletions may impact on tumor progression and therapy resistance by reducing responsiveness to p53-induced apoptosis.
Alternatively, the reduced ability of apoptosis-proficient TC252 cells to growth-arrest in response to elevated levels of p53 may be envisaged as compatible with the hypothesis that conflicting growth signals can trigger apoptosis (Lowe et al., 1993; Hermeking et al., 1995) . The growth promoting activity opposing p53 may be conferred by an oncogene such as cMYC (Lowe et al., 1993; Wagner et al., 1994; Hermeking et al., 1995) . It remains to be established, if this or other oncogenes, which have been reported to be highly expressed in EFT (McKeon et al., 1988; Vecchio et al., 1989; Sollazzo et al., 1999) , vary in expression between EFT cell lines with different apoptotic propensity. In contrast, STA-ET-2.1 and STA-ET-2.2 cells showed only a minimal growth reduction of p53-transfected cells despite the absence of apoptosis. Here, high level BCL2 and low level BAX and APAF1 expression may have been sufficient to protect from p53-induced cell death. Previously, overexpression of E2F has been shown to result in apoptosis when cell proliferation is restricted or when wt p53 expression is activated (Qin et al., 1994; Wu and Levine, 1994) . Loss of Rb expression or deregulation of the phosphorylation of Rb, due either to increased cyclin D1 or CDK4 expression or to INK4A gene mutation results in increased levels of active E2F. When occurring in tumor cells, such alterations can also be understood to predispose a cell to p53-induced apoptosis (as reviewed in Gottlieb and Oren, 1996) . In line with this hypothesis, we have previously shown that, among EFT cell lines, apoptosis-resistant SAL2 express relatively low levels of cyclin D1 (Kovar et al., 1997) . In contrast, the cell line SK-N-MC, which has been demonstrated in the same study to lack Rb expression resulting in increased INK4A gene transcription, was in fact among the cell lines with the highest apoptotic propensity in response to ectopic p53 expression. In addition, although INK4A is frequently deleted in EFT cell lines, no correlation of p53-induced apoptosis to the status of this gene was observed in the present study.
Another result of our transient transfection experiments was that lipofectamine-mediated DNA transfer per se triggered apoptosis in p53-sensitive cell lines, but only in the presence of endogenous wt p53 expression extending earlier observations obtained from calcium phosphate-mediated transfection (Renzing and Lane, 1995) . This effect is considered to be because of the presence of low abundancy DNA strand breaks in the transfected DNA, and was most pronounced in the wt p53-expressing cell line VH64. Paradoxically, this cell line was found to be completely resistant to X-rayinduced cell death despite proper activation of p53. While irradiation resulted in Ser15 phosphorylation of p53, DNA transfection did not. Thus, downstream signaling may differ between differently modified p53 species in VH64 cells. Alternatively, irradiation may have activated a protection mechanism blocking the apoptotic program in this cell line.
The transfection-mediated cytotoxicity was found to mask the residual apoptotic activity of the tumor-derived p53 mutant R273 H in the presence of endogenous wt p53. While p53-R273 H was unable to transactivate reporter genes in a yeast-based assay (Di Como and Prives, 1998) , this mutant has previously been demonstrated to retain DNA binding activity to the p53 response elements of at least a subset of p53 target genes (Park et al., 1994; Gorgoulis et al., 1998) . In addition, for several carcinoma cell lines carrying homozygous p53-R273 H mutations, endogenous p53 has been demonstrated to be transcriptionally active (Park et al., 1994) . It is, therefore, possible that the mutant mediates its residual apoptotic function via transcriptional activation of only a subset of p53 target genes.
As demonstrated for SAL2 in comparison with TC252 cells and discussed above, a low apoptotic response was accompanied by a more pronounced cell cycle arrest response in the surviving fraction of transiently p53 transfected cells and vice versa. Consequently, cell lines refractory to p53-induced apoptosis were not generally p53 resistant. However, upon prolonged incubation of EFT cell lines in the absence of selective pressure that would maintain high-level p53 expression, a relaxation of the cell cycle arrest in the surviving fraction was noted. We believe that this situation may reflect the p53 response in tumor cells retaining wt p53 function during anticancer therapy of patients. Chemo-as well as radiotherapy is given to patients in cycles that may allow for selection of tumor cell subclones transiently refractory to p53-induced apoptosis. Such transiently p53-resistant tumor cells may display a prolonged cell cycle arrest rendering them even more refractory to the cytotoxic effects of chemotherapy. Upon repetitive induction of p53, tumor cells resistant to p53-induced apoptosis will consequently be further enriched. As previously demonstrated for ras-transformed rat embryo fibroblasts expressing temperature-sensitive p53, stably p53-resistant subclones may emerge from apoptosis-proficient cells when wt p53 function is induced (Pietenpol et al., 1996) . Thus, insensitivity to the apoptotic activity of transiently overexpressed p53 may be considered as a mechanism contributing to the development of treatment-resistant disease in EFT and possibly other neoplasms retaining wt p53.
Materials and methods
Cell lines
All EFT cell lines were propagated on fibronectin-coated plastics in RPMI 1640+10% fetal calf serum at 371C. VH64 was kindly supplied by F Van Valen (Department of Pediatrics, University of Muenster, Germany). SAL2 was provided by G Hamilton (Department of Surgery, University Hospital Vienna, Austria). SK-N-MC and IARC-EW2 were obtained from J Biedler (Memmorial Sloan Kettering Cancer Center, New York, USA) and GM Lenoir (International Agency for Research on Cancer, Lyon, France), respectively. TC252 was kindly supplied by T Triche (Department of Pathology, Children's Hospital, Los Angeles, USA). The STA-ET series of cell lines was established at the Children's Cancer Research Institute (Vienna, Austria). Note that SAL2 and STA-ET-1 were both obtained from the same tumor independently at two different institutions. STA-ET-2.1 and STA-ET-2.2 were generated from a biopsy of the primary tumor and a bone marrow infiltrate of one patient. The p53, INK4A, and MDM2 gene status of these cell lines has previously been described (Kovar et al., 1993a (Kovar et al., , 1997 as summarized in Table 1 .
Irradiation and cytotoxicity assay X-ray treatment of EFT cell lines (3-12 Gy) was performed using a Phillips RT100 irradiation device (1.7 mm aluminum filter, 100 kV) at 12.5 Gy/min. After treatment, cells were incubated at 371C for the indicated times before irradiationinduced cytotoxicity was assessed by a vital dye exclusion test. Since dead and dying cells tend to detach from the culture plate, the floating and attached cells were separately collected, stained with trypan blue and counted (Lassus et al., 1996) .
Plasmids and transient transfections
The wt p53 and p53-273 H expression plasmids pC53-SN3 and pC53-4.2N3 were kindly supplied by B Vogelstein (John Hopkins Oncology Center, Baltimore, USA). The nuclear bgalactosidase expression vector pCMV-SVNL has previously been described (Kovar et al., 1996) . The GFP expression vector pEGFP-CMV was previously described (Kovar et al., 2000b) . DNA transfer into logarithmically growing EFT cell lines (0.5-1.0 Â 10 6 cells) was accomplished by lipofection of Qiagen (Hilden, Germany) purified plasmid DNA (10 mg) using either lipofectin or LipofectAMIN PLUS TM reagent followed by a 24 or 3 h incubation in serum-free optimum medium, respectively, according to the manufacturer's (Life Technologies, Paisley, UK) instructions.
Flow cytometry
Fluorescence-activated cell sorter analyses (FACS) were performed with a FACSCalibur (BD, Sunnyvale, CA, USA). DNA content in transiently p53-or control-transfected cells was determined essentially according to a previously published protocol (Haupt et al., 1995) . If not otherwise stated in the text, 44 h after transfection, adherent cells were combined with cells that had detached from the plastic and were fixed with 70% ice-cold ethanol for at least 1 h. After rehydration and washing in PBS, cells were stained with antibodies CM1 or DO1 (a kind gift of B Vojtesek, Masaryk Memorial Cancer Institute, Brno) for detection of p53 or with an antibody to bgalactosidase (Z3781, Promega, Madison, WI, USA), followed by PI (50 mg/ml). FITC-conjugated secondary anti-rabbit (F205) or anti-mouse (F313) antibodies were from DAKO (Vienna, Austria). DNA-content in FITC-positive and negative cells was assessed by a two-color FACS analysis.
Northern blotting
RNA extraction and Northern blotting were performed according to standard procedures. The WAF-1-specific probe was obtained from B Vogelstein (John Hopkins Oncology Center, Baltimore, USA). Probes for human MDM2 exons 3-5 were generated by PCR amplification using primers ex3F (TGTCAATACCAACATGTCTG) with ex5R (CTGTGCTCTTTCACAGAGAAG). The PIG3 probe was an EST clone N7S824 kindly supplied by DS Haines (The Fels Institute for Cancer Research and Molecular Biology, Temple University School of Medicine, Philadelphia, PA, USA). A partial human BAX cDNA probe (p18CL7 M) was received from SJ Korsmeyer (Howard Hughes Medical Institute, Boston, MA, USA). The probe for DR5 (human TRAIL-R2) was purchased from Alexis Corporation (Lausen, Switzerland).
Western blotting
For the evaluation of the expression of apoptosis-related proteins, whole-cell extracts were prepared by boiling in SDS sample buffer and immunoblot analysis was performed according to the standard procedures. Antibodies to BCL2 (100), BAX (N-20), and BCL-X 1 S (S-18) were purchased from Santa Cruz (Santa Cruz, CA, USA). The caspase-9-specific antibody (Ab2) was purchased from Oncogene Research Products (Calbiochem-Novabiochem, Schwalbach, Germany). The polyclonal antiserum to phospho-p53 (Ser15) was from New England BioLabs (Frankfurt am Main, Germany).
Monoclonal antibodies to caspase 8 (C15) and to poly (ADP-ribose) polymerase (PARP) (C-2-10), and the polyclonal rabbit serums to APAF-1 and to p53 (CM1) were kindly provided by I Schmitz (DKFZ, Heidelberg, Germany). G Poirier (Centre Hospitalier Universitaire de Quebec, Canada), X Wang (University of Texas South Western Medical Center, Dallas, TX, USA) and B Vojtesek (Masaryk Memorial Cancer Institute, Brno), respectively.
